NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Announces Publication of AZX1101 Patent Application
Development stage biopharmaceutical company AzurRx BioPharma, Inc. (NASDAQ: AZRX) this morning announced that the United States Patent and Trademark Office has published patent application number 15/519424, entitled ‘Hybrid Proteinaceous Molecule Capable of Inhibiting at Least One Antibiotic and Pharmaceutical Composition Containing It’, covering the company’s AZX1101 recombinant enzyme for the prevention of antibiotic-induced diarrhea and hospital-acquired C. difficile infections. “We believe that AZX1101, a non-systemic protein, can preserve healthy gastrointestinal flora by inhibiting antibiotics in the GI tract and thus prevent the development of antibiotic induced diarrhea and bacterial infections,” Thijs Spoor, CEO of AzurRx, stated in the news release. “We…